ドセタキセルによって涙道閉塞をきたした3例

Three cases of occlusion of lacrimal passage following systemic docetaxel

　抗癌薬ドセタキセルで加療中の3症例に涙点閉鎖または涙小管閉塞が生じた。第1例は61歳男性で，胃癌に対するドセタキセル投与開始から2か月後に右眼の上下涙点と左眼の上涙点の閉鎖が生じた。第2例は54歳女性で，乳癌に対するドセタキセル投与開始から9か月後に両眼の上下涙点の閉鎖が生じた。第3例は61歳女性で，乳癌に対するドセタキセル投与開始から5か月後に右眼下涙点の閉鎖が生じた。涙点切開またはシリコーン管留置を行い，涙小管閉塞がない場合には涙道機能が回復した。ドセタキセルを投与中の患者には涙道閉鎖の可能性があり，早期発見または予防が望ましい。

　Occlusion of lacrimal passage developed in 3 patients receiving systemic docetaxel for carcinoma. One was a 61-year-old male with stomach cancer. After 2months of docetaxel therapy,he developed occlusion of both lacrimal puncta in the right eye and upper punctum in the left. The second was a 54-year-old female with breast cancer. After 9months of docetaxel,she developed occlusion of both lacrimal puncta in both eyes. The third was a 61-year-old female with breast cancer. She developed occlusion of lower punctum in the right eye. All the cases were treated by incision of lacrimal punctum or silicone intubation. The lacrimal passage recovered its function in eyes without occlusion of lacrimal canaliculus. We advocate due precaution in patients under docetaxel therapy with this possibility in mind.